Vial, a tech-driven CRO focused on next-generation clinical trial management, has announced a strategic partnership with Documenso, an open-source digital signing platform. This collaboration aims to revolutionize document signing practices in the life sciences sector, offering an alternative to traditional platforms like DocuSign. The partnership will focus on meeting the stringent requirements of CFR Part 11 compliance, a set of FDA guidelines for electronic recordkeeping and signatures in regulated sectors.
Simon Burns, CEO of Vial, emphasized the partnership’s potential to innovate document management in the life sciences, aligning with the demands of 21 CFR Part 11. On the other hand, Timur, CEO of Documenso, highlighted the platform’s scalability and the benefits of Commercial Open Source (COSS) principles.